JP2021527031A5 - - Google Patents
Info
- Publication number
- JP2021527031A5 JP2021527031A5 JP2020566701A JP2020566701A JP2021527031A5 JP 2021527031 A5 JP2021527031 A5 JP 2021527031A5 JP 2020566701 A JP2020566701 A JP 2020566701A JP 2020566701 A JP2020566701 A JP 2020566701A JP 2021527031 A5 JP2021527031 A5 JP 2021527031A5
- Authority
- JP
- Japan
- Prior art keywords
- cocrystal
- pharmaceutically acceptable
- acceptable salt
- subject
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024030700A JP7841008B2 (ja) | 2018-05-30 | 2024-02-29 | セピアプテリンの薬学的に許容される塩 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862678025P | 2018-05-30 | 2018-05-30 | |
| US62/678,025 | 2018-05-30 | ||
| US201862726612P | 2018-09-04 | 2018-09-04 | |
| US62/726,612 | 2018-09-04 | ||
| US201962822336P | 2019-03-22 | 2019-03-22 | |
| US62/822,336 | 2019-03-22 | ||
| GC201937661 | 2019-05-28 | ||
| GC2019/37661 | 2019-05-28 | ||
| PCT/US2019/034505 WO2019232120A1 (en) | 2018-05-30 | 2019-05-30 | Pharmaceutically acceptable salts of sepiapterin |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024030700A Division JP7841008B2 (ja) | 2018-05-30 | 2024-02-29 | セピアプテリンの薬学的に許容される塩 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021527031A JP2021527031A (ja) | 2021-10-11 |
| JP2021527031A5 true JP2021527031A5 (enExample) | 2022-06-07 |
| JP7778477B2 JP7778477B2 (ja) | 2025-12-02 |
Family
ID=68699017
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020566701A Active JP7778477B2 (ja) | 2018-05-30 | 2019-05-30 | セピアプテリンの薬学的に許容される塩 |
| JP2024030700A Active JP7841008B2 (ja) | 2018-05-30 | 2024-02-29 | セピアプテリンの薬学的に許容される塩 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024030700A Active JP7841008B2 (ja) | 2018-05-30 | 2024-02-29 | セピアプテリンの薬学的に許容される塩 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12637465B2 (enExample) |
| EP (1) | EP3807279B1 (enExample) |
| JP (2) | JP7778477B2 (enExample) |
| KR (1) | KR20210038848A (enExample) |
| CN (1) | CN112543758A (enExample) |
| AU (2) | AU2019277372B2 (enExample) |
| BR (1) | BR112020024332A2 (enExample) |
| CA (1) | CA3102070A1 (enExample) |
| CL (1) | CL2020003101A1 (enExample) |
| CO (1) | CO2020016582A2 (enExample) |
| IL (1) | IL279101A (enExample) |
| MX (1) | MX2020012978A (enExample) |
| WO (1) | WO2019232120A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110312721A (zh) | 2016-11-29 | 2019-10-08 | 显莎制药公司 | 墨蝶呤的多晶型物 |
| WO2018102315A1 (en) | 2016-11-29 | 2018-06-07 | Censa Pharmaceuticals Inc. | Polymoprhs of sepiapterin and salts thereof |
| MX2020002271A (es) | 2017-09-01 | 2020-10-05 | Ptc Therapeutics Mp Inc | Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas. |
| CA3102105A1 (en) * | 2018-05-30 | 2019-12-05 | Ptc Therapeutics Mp, Inc. | Compositions and methods for increasing tetrahydrobiopterin plasma exposure |
| JP7778477B2 (ja) * | 2018-05-30 | 2025-12-02 | ピーティーシー セラピューティクス エムピー，インコーポレイテッド | セピアプテリンの薬学的に許容される塩 |
| JP7502197B2 (ja) | 2018-05-30 | 2024-06-18 | ピーティーシー セラピューティクス エムピー，インコーポレイテッド | セピアプテリン血漿曝露を増加させるための方法 |
| LT4009978T (lt) | 2019-08-05 | 2024-11-25 | Ptc Therapeutics Mp, Inc. | Sepiapterino ir jo metabolitų panaudojimas spinduliuotės poveikio gydymui |
| IL291565B1 (en) | 2019-09-25 | 2026-04-01 | Ptc Therapeutics Inc | Method for treating phenylalanine irregularity |
| CA3165636A1 (en) | 2020-01-24 | 2021-07-29 | Neil Smith | Methods for treating parkinson's disease with sepiapterin |
| CN114621198B (zh) * | 2020-12-11 | 2025-01-21 | 北京夏禾科技有限公司 | 有机电致发光材料及其器件 |
| US12691119B2 (en) | 2021-02-09 | 2026-07-28 | Ptc Therapeutics Mp, Inc. | Methods for treating covid-19 with sepiapterin |
| IL305037A (en) | 2021-02-09 | 2023-10-01 | Ptc Therapeutics Mp Inc | Methods of treating glioblastomas with spiafatrin |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5925323A (ja) | 1982-03-03 | 1984-02-09 | 鐘淵化学工業株式会社 | プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤 |
| US5910304A (en) | 1982-12-13 | 1999-06-08 | Texas A&M University System | Low-dose oral administration of interferons |
| CA1320905C (en) | 1986-11-06 | 1993-08-03 | Joseph M. Cummins | Treatment of immuno-resistant disease |
| US5753656A (en) * | 1994-08-05 | 1998-05-19 | Suntory Limited | Method for treating spinocerebellar degeneration |
| WO1997007236A1 (en) | 1995-08-18 | 1997-02-27 | Landry Donald W | Detection of organic compounds through regulation of antibody-catalyzed reactions |
| US6036949A (en) | 1998-03-05 | 2000-03-14 | Amarillo Biosciences, Inc. | Treatment of fibromyalgia with low doses of interferon |
| US8188043B2 (en) | 1999-07-28 | 2012-05-29 | The Board Of Trustees Of The Leland Stanford Jr. University | Nicotine in therapeutic angiogenesis and vasculogenesis |
| FR2859996B1 (fr) | 2003-09-19 | 2006-02-03 | Aventis Pharma Sa | Solvat acetonique du dimethoxy docetaxel et son procede de preparation |
| JP2007509909A (ja) | 2003-10-31 | 2007-04-19 | アルタナ ファルマ アクチエンゲゼルシャフト | 呼吸器疾患の治療のためのｂｈ４の使用 |
| JP5184783B2 (ja) | 2003-11-17 | 2013-04-17 | バイオマリン ファーマシューティカル インコーポレイテッド | テトラヒドロビオプテリン、及びテトラヒドロビオプテリン類似体の製造方法 |
| CA2545968C (en) | 2003-11-17 | 2010-03-09 | Merck Eprova Ag | Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride |
| PT3138566T (pt) | 2003-11-17 | 2022-02-02 | Biomarin Pharm Inc | Tratamento de fenilcetonúria com bh4 |
| CN101132776A (zh) | 2004-11-17 | 2008-02-27 | 生物马林药物股份有限公司 | 稳定的四氢生物喋呤片剂制剂 |
| US20100130500A1 (en) | 2004-12-08 | 2010-05-27 | Biomarin Pharmaceutical Inc. | Methods and compositions for the treatment of pulmonary hypertension of the newborn |
| WO2006118322A1 (en) | 2005-04-28 | 2006-11-09 | Shiratori Pharmaceutical Co., Ltd. | Method for producing hydrazone derivatives |
| US20080075666A1 (en) | 2006-08-25 | 2008-03-27 | Dudley Samuel C Jr | Methods and compositions for treating diastolic dysfunction |
| KR20160065998A (ko) | 2007-04-11 | 2016-06-09 | 바이오마린 파머수티컬 인크. | 테트라하이드로바이오프테린 투여 방법, 관련 조성물 및 측정 방법 |
| LT2262790T (lt) | 2008-03-10 | 2017-08-25 | Takeda Pharmaceutical Company Limited | Benzimidazolo junginio kristalas |
| WO2010017570A2 (de) | 2008-08-12 | 2010-02-18 | Orpha Swiss Gmbh | Pharmazeutische darreichungsform enthaltend tetrahydrobiopterin |
| EP2382216A1 (en) | 2008-12-23 | 2011-11-02 | Boehringer Ingelheim International GmbH | Salt forms of organic compound |
| IN2012DN01453A (enExample) | 2009-08-20 | 2015-06-05 | Novartis Ag | |
| JP5066756B2 (ja) * | 2010-04-22 | 2012-11-07 | 学校法人日本大学 | 脳機能障害予防・改善用の薬剤及び飲食物 |
| US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| CA2828685C (en) | 2011-03-01 | 2018-05-29 | Rubicon Research Private Limited | Stable compositions of tetrahydrobiopterin |
| US9216178B2 (en) | 2011-11-02 | 2015-12-22 | Biomarin Pharmaceutical Inc. | Dry blend formulation of tetrahydrobiopterin |
| JP6084967B2 (ja) | 2012-05-07 | 2017-02-22 | 白鳥製薬株式会社 | セピアプテリン及びテトラヒドロラクトイルプテリンの製造法 |
| WO2017218421A1 (en) * | 2016-06-13 | 2017-12-21 | Meharry Medical College | Modulation of the nitric oxide synthase pathway for oral health |
| WO2018019931A1 (en) | 2016-07-29 | 2018-02-01 | Dipharma S.A. | Pharmaceutical composition kit comprising sapropterin dihydrochloride |
| WO2018102315A1 (en) | 2016-11-29 | 2018-06-07 | Censa Pharmaceuticals Inc. | Polymoprhs of sepiapterin and salts thereof |
| CN110312721A (zh) | 2016-11-29 | 2019-10-08 | 显莎制药公司 | 墨蝶呤的多晶型物 |
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| MX2020002271A (es) | 2017-09-01 | 2020-10-05 | Ptc Therapeutics Mp Inc | Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas. |
| CA3102105A1 (en) | 2018-05-30 | 2019-12-05 | Ptc Therapeutics Mp, Inc. | Compositions and methods for increasing tetrahydrobiopterin plasma exposure |
| JP7778477B2 (ja) * | 2018-05-30 | 2025-12-02 | ピーティーシー セラピューティクス エムピー，インコーポレイテッド | セピアプテリンの薬学的に許容される塩 |
| JP7502197B2 (ja) | 2018-05-30 | 2024-06-18 | ピーティーシー セラピューティクス エムピー，インコーポレイテッド | セピアプテリン血漿曝露を増加させるための方法 |
| LT4009978T (lt) | 2019-08-05 | 2024-11-25 | Ptc Therapeutics Mp, Inc. | Sepiapterino ir jo metabolitų panaudojimas spinduliuotės poveikio gydymui |
| IL291565B1 (en) | 2019-09-25 | 2026-04-01 | Ptc Therapeutics Inc | Method for treating phenylalanine irregularity |
-
2019
- 2019-05-30 JP JP2020566701A patent/JP7778477B2/ja active Active
- 2019-05-30 US US17/059,887 patent/US12637465B2/en active Active
- 2019-05-30 EP EP19811127.0A patent/EP3807279B1/en active Active
- 2019-05-30 AU AU2019277372A patent/AU2019277372B2/en active Active
- 2019-05-30 KR KR1020207037815A patent/KR20210038848A/ko not_active Ceased
- 2019-05-30 CN CN201980050845.2A patent/CN112543758A/zh active Pending
- 2019-05-30 CA CA3102070A patent/CA3102070A1/en active Pending
- 2019-05-30 BR BR112020024332-9A patent/BR112020024332A2/pt unknown
- 2019-05-30 MX MX2020012978A patent/MX2020012978A/es unknown
- 2019-05-30 WO PCT/US2019/034505 patent/WO2019232120A1/en not_active Ceased
-
2020
- 2020-11-27 CL CL2020003101A patent/CL2020003101A1/es unknown
- 2020-11-30 IL IL279101A patent/IL279101A/en unknown
- 2020-12-29 CO CONC2020/0016582A patent/CO2020016582A2/es unknown
-
2024
- 2024-02-29 JP JP2024030700A patent/JP7841008B2/ja active Active
-
2025
- 2025-02-13 AU AU2025201002A patent/AU2025201002A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024063143A5 (enExample) | ||
| ZA202001390B (en) | Crystalline forms | |
| KR102425226B1 (ko) | Jak 저해제를 포함하는 제약 조성물 | |
| AU2025213591A1 (en) | Methods of treating neurological and psychiatric disorders | |
| JP6389498B2 (ja) | ニトロカテコールの投与計画 | |
| JP2016503010A5 (enExample) | ||
| JP2014037426A5 (enExample) | ||
| JP2021525729A5 (enExample) | ||
| JP2015500236A5 (enExample) | ||
| HRP20231533T1 (hr) | Kristalni oblici od (s)-1-(4-fluorofenil)-1-(2-(4-(6-(1-metil-1h-pirazol-4-il)pirolo[2,1-f][1,2,4 ]triazin-4-il)piperazinil)-pirimidin-5-il)etan-1-amina i postupci priprave | |
| JP2015509534A5 (enExample) | ||
| JP2022502500A5 (enExample) | ||
| JP2010505961A5 (enExample) | ||
| JP2015509972A5 (enExample) | ||
| JP2017538753A5 (enExample) | ||
| JP2013506670A5 (enExample) | ||
| RU2003121307A (ru) | (диазоло-пиридинил)-пиримидины для применения в лечении нарушений центральной нервной системы и диабета | |
| JP2018537513A5 (enExample) | ||
| JP2015500223A5 (enExample) | ||
| JP5124471B2 (ja) | 置換二環式ピリミドン誘導体 | |
| JP2024160326A (ja) | Ｅａａｔ２活性化因子およびその使用方法 | |
| JP2022514537A5 (enExample) | ||
| WO2012031383A1 (zh) | 酰胺类化合物 | |
| IL292466B2 (en) | Isoquinolinone derivatives, method for preparing the same, and pharmaceutical composition for preventing or treating poly(adp-ribose) polymerase-1-related diseases, comprising the same as active ingredient | |
| JP2010520176A5 (enExample) |